Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lonitoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lomond’s Lonitoclax IND Cleared by FDA for Chronic Lymphocytic Leukemia
Details : Lonitoclax has a best-in-class potency and selectivity against BCL-2. Currently, it is being evaluated for the treatment of chronic lymphocytic leukemia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Lead Product(s) : Lonitoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?